Fortunately, a lot of knowledge will be gained from the more than 140 human studies ongoing in PD, which includes thirteen α-synuclein targeting treatments, e.g., antibodies, vaccines, gene therapies, and small-molecule compounds, and four potential GBA targeting treatments, one gene therapy, and three small-molecule compounds. The gene discussed is SNCA; the disease is Parkinson disease.